Introduction Vaginal atrophy (VA) is an irreversible involution of the mucous membranes and tissues of the vagina following the drop in estrogen that commonly occurs in women during menopause (1). Due to a lengthening of the average lifespan and longer life expectancy after menopause, vaginal atrophy is destined to become a clinical problem with an increasingly greater epidemiological significa...

Between 4 and 6 of every 10 women undergoing menopause suffer from symptoms related to vaginal atrophy. Dyspareunia, in relation to vaginal dryness, can lead to sexual dysfunction. Vaginal hormone treatment has been regarded as the ideal treatment for vaginal atrophy management. Laser treatment is used to reduce the symptoms generated by vaginal atrophy, and to offer patients an alternative to ...

BACKGROUND Vaginal atrophy, the thinning and drying of vaginal mucosa, is associated with menopause. The standard estrogen treatment is not suitable for all women. OBJECTIVE To investigate the effects of oral sea buckthorn (SB) oil supplementation on vaginal atrophy. METHOD A total of 116 postmenopausal women experiencing symptoms of vaginal dryness, itching or burning were randomized to th...

BACKGROUND Vaginal atrophy is a common complication in menopause which does not improve with time and, if untreated, can affect the quality of life for women. The aim of this study was to compare the effectiveness of the vaginal cream of hyaluronic acid and conjugated estrogen (Premarin) in treatment of vaginal atrophy. METHODS This study was a randomized controlled clinical trial on 56 menop...

Menopause, due to the physiological decrease in the estrogens levels, is often associated with many symptoms related to vaginal atrophy such vaginal dryness, dyspareunia, burning, itching, decreasing in libido and therefore a worsening of the quality of life and in particular of the sexual activity. There are many pharmacological remedies to solve these events, first of all hormone replacement ...

INTRODUCTION Ospemifene (Osphena, Shionogi Inc, Florham, NJ, USA) is an estrogen agonist and antagonist approved by the U.S. Federal Drug Administration for the treatment of "moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause." Although published, peer-reviewed, placebo-controlled studies have shown objective improvement in dyspareunia and in vaginal atrop...

Up to half of all postmenopausal women will experience changes in the genitourinary tract induced by the hypoestrogenic state, collectively known as vaginal atrophy. Vaginally administered local estrogen therapy (LET) is the standard of care for symptoms of vaginal atrophy that do not respond to nonhormonal interventions. Several LET formulations are available, and choice of therapy is based la...

INTRODUCTION Vaginal dryness due to vaginal atrophy is a common complaint of postmenopausal women, interfering with sexual function and quality of life. Hormone replacement therapy is the only effective therapy but with known risks that leave unmet medical needs. A new product, ZP-025 vaginal gel, containing purified (dialyzed lyophilized) bovine colostrum, has been developed for the treatment ...

OBJECTIVE This study aims to determine the emotional and physical impact of vaginal atrophy on North American postmenopausal women and their male partners. METHODS A weighted sample of 1,000 married or cohabiting North American postmenopausal women aged 55 to 65 years with vaginal discomfort and 1,000 male partners of postmenopausal women aged 55 to 65 years who experienced vaginal discomfort...